Disorders of Phosphate: Hyperphosphatemia

  • Alluru S. ReddiEmail author


Hyperphosphatemia is defined as serum [Pi] > 4.5 mg/dL. Spurious increase in serum [Pi] is called pseudohyperphosphatemia . It is rather rare but has been described in conditions of hyperglobulinemia, hypertriglyceridemia, and hyperbilirubinemia. This spurious increase has been attributed to the interference of proteins and triglycerides in the colorimetric assay of phosphate. The causes of true hyperphosphatemia can be grouped under three major categories: (1) addition of phosphate from the intracellular fluid (ICF) to extracellular fluid (ECF) compartment; (2) a decrease in renal excretion of phosphate; and (3) drugs. In clinical practice, acute and chronic kidney diseases are probably the most significant causes of hyperphosphatemia.


Hyperphosphatemia Pseudohyperphosphatemia Hyperglobulinemia Hypertriglyceridemia Hyperbilirubinemia Kidney injury Sodium phosphate 


  1. 1.
    Chertow GM, Burke SK, Raggi P, Treat to goal working group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–52.PubMedCrossRefGoogle Scholar
  2. 2.
    Braun J, Asmus H-G, Holzer H, et al. Long term comparison of a calcium free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62:104–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to dialysis. Kidney Int. 2005;68:1815–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium calbonate or sevelamer. Kidney Int. 2007;72:1255–61.PubMedCrossRefGoogle Scholar
  5. 5.
    Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME. Phosphate binder impact on bone remodeling and coronary calcification–results from the BRiC study. Nephron Clin Pract. 2008;110:273–83.CrossRefGoogle Scholar
  6. 6.
    Qunibi W, Moustafa M, Muenz LR, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The calcium acetate renagel evaluation-2 (CARE-2) Study. Am J Kidney Dis. 2008;51:952–65.PubMedCrossRefGoogle Scholar
  7. 7.
    Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108:c278–83.CrossRefGoogle Scholar
  8. 8.
    Molony DA, Stephens BW. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. Adv Chronic Kidney Dis. 2011;18:120–31.PubMedCrossRefGoogle Scholar
  9. 9.
    St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the dialysis clinical outcomes revisited (DCOR) randomized trial using claims data. Am J Kidney Dis. 2008;51:445–54.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. 12.
    Kuro-O M. Phosphate and KLOTHO. Kidney Int. 2011;79(suppl 121):S20–3.Google Scholar
  2. 10.
    Hruska KA, Levi M, Slatopolsky E. Disorders of phosphorus, calcium, and magnesium metabolism. In: Coffman TM, Falk RJ, Molitoris BA et al, Editors. Schrier’s diseases of the kidney. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 2116–81.Google Scholar
  3. 11.
    Smogorzewski MJ, Rude RK, Yu ASL. Disorders of calcium, magnesium, and phosphate balance. In: Taal MW, Chertow GM, Marsden PA et al, Editors. Brenner & Rector’s the kidney. 9th ed. Philadelphia: Saunders; 2012. pp. 689–725.CrossRefGoogle Scholar
  4. 13.
    Tonelli M, Pannu N. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Medicine Division of Nephrology and HypertensionRutgers New Jersey Medical SchoolNewarkUSA

Personalised recommendations